[1] [1] GRALINSKI L E, MENACHERY V D. et al. Return of the coronavirus: 2019-nCoV ［J］. Viruses, 2020, 12(2): 135-143.

[2] [2] CAO M, SU X J, JIANG S B. et al. Broad-spectrum anti-coronavirus vaccines and therapeutics to combat the current COVID-19 pandemic and future coronavirus disease outbreaks ［J］. Stem Cell Reports, 2021, 16(3): 398-411.

[3] [3] LU R, ZHAO X, LI J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding ［J］. Lancet, 2020, 395(10224): 565-574.

[4] [4] LIU S J, LENG C H, LIEN S P, et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates ［J］. Vaccine, 2006, 24(16): 3100-3108.

[5] [5] NARAYANAN K, CHEN C J, MAEDA J, et al. Nucleocapsid-independent specific viral RNA packaging via viral envelope protein and viral RNA signal ［J］. Journal of Virolgy, 2003, 77(5): 2922-2927.

[6] [6] TAN Y J, GOH P Y, FIELDING B C, et al. Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers ［J］. Clinical and Diagnostic Laboratory Immunology, 2004, 11(2): 362-371.

[7] [7] SHI Y, YI Y, LI P, et al. Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay ［J］. Journal of Clinical Microbiology, 2003, 41(12): 5781-5782.

[8] [8] SAIKATENDU K S, JOSEPH J S, SUBRAMANIAN V, et al. Ribonucleocapsid formation of severe acute respiratory syndrome coronavirus through molecular action of the N-terminal domain of N protein ［J］. Journal of Virolgy, 2007, 81(8): 3913-3921.

[9] [9] ZHENG M, GAO Y, WANG G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients ［J］. Cellular & Molecular Immunology, 2020, 17(5): 533-535.

[10] [10] KUMAR J, QURESHI R, SAGURTHI S R, et al. Designing of nucleocapsid protein based novel multi-epitope vaccine against SARS-COV-2 using immunoinformatics approach ［J］. Nature Public Health Emergency Collection, 2020(2): 1-16.

[11] [11] IWARSON S, TABOR E, THOMAS H C, et al. Protection against hepatitis B virus infection by immunization with hepatitis B core antigen ［J］. Gastroenterology, 1985, 88(3): 763-767.

[13] [13] DUTTA N K, MAZUMDAR K, GORDY J T. et al. The nucleocapsid protein of SARS-CoV-2: a target for vaccine development ［J］. Journal of Virolgy, 2020, 94(13): e00647-20.

[14] [14] ZENG W, LIU G, MA H, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein ［J］. Elsevier Public Health Emergency Collection, 2020, 527(3): 618-623.

[15] [15] EATON K A, SUERBAUM S, JOSENHANS C, et al. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes ［J］. Infection and Immunity, 1996, 64(7): 2445-2448.

[16] [16] SHIM J U, LEE S E, HWANG W, et al. Flagellin suppresses experimental asthma by generating regulatory dendritic cells and T cells ［J］. Journal of Allergy and Clinical Immunology, 2016, 137(2): 426-435.

[17] [17] NGUYEN C T, HONG S H, SIN J I, et al. Flagellin enhances tumor-specific CD8+T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model ［J］. Vaccine, 2013, 31(37): 3879-3887.

[18] [18] LEE S E, KIM S Y, JEONG B C, et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity ［J］. Infection and Immunity, 2006, 74(1): 694-702.

[21] [21] GUO L, REN L, YANG S, et al l. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) ［J］. Clinical Infectious Diseases, 2020, 71(15): 778-785.

[22] [22] ADMYRE C, JOHANSSON S M, PAULIE S, et al. Direct exosome stimulation of peripheral human T cells detected by ELISPOT ［J］. European Journal of Immunology, 2006, 36(7): 1772-1781.

[23] [23] PANG H, LIU Y, HAN X, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine ［J］. Journal of General Virology, 2004, 85(10): 3109-3113.

[24] [24] ZHU M S, PAN Y, CHEN H Q, et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine ［J］. Immunology Letters, 2004, 92(3): 237-243.

[25] [25] GAO W, TAMIN A, SOLOFF A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys ［J］. Lancet, 2003, 362(9399): 1895-1896.

[26] [26] VERMA V, TAN W, PUTH S, et al. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB ［J］. Journal of Translational Medicine, 2016, 14(1): 135.

[27] [27] HONG S H, BYUN Y H, NGUYEN C T, et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection ［J］. Vaccine, 2012, 30(2): 466-474.

[28] [28] NGUYEN C T, KIM S Y, KIM M S, et al. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice ［J］. Vaccine, 2011, 29(34): 5731-5739.